Using animal models to develop new treatments for tuberculosis

Seminars in Respiratory and Critical Care Medicine

Volumn 29, Issue 5, 2008, Pages 542-551

  Nuermberger, Eric ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Animal models; Latent tuberculosis infection; Treatment; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; CORTICOSTEROID; ETHAMBUTOL; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SPARFLOXACIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG RESEARCH; EXPERIMENTAL INFECTION; EXPERIMENTAL MODEL; GUINEA PIG; HUMAN; MONOTHERAPY; MOUSE STRAIN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HUMANS; MICE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 53549104456     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0028-1085705     Document Type: Review

References (54)

1. Grosset J, Ji B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA, eds. Mycobacteria, vol 2: Chemotherapy. New York: Chapman & Hall; 1998:51-97
2. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978;53:5-12
3. Grosset J, Grumbach F, Rist N. Le role de la rifampicine dans la phase ultime du traitement de la tuberculose murine experimentale. Rev Fr Mal Respir 1978;6:515-520
4. Grumbach F. La duree optimale de l'antibiotherapie par l'association isoniazide + rifampicine dans la tuberculose experimentale de la souris. Etude de la phase post-therapeutique. Epreuve de la cortisone. Rev Fr Mal Respir 1967;3:625-634
5. Mitchison DA. Basic concepts in the chemotherapy of tuberculosis. In: Gangadharam PRJ, Jenkins PA, eds. Mycobacteria, vol 2: Chemotherapy. New York: Chapman & Hall; 1998:15-50
6. Warner DF, Mizrahi V. Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. Clin Microbiol Rev 2006;19:558-570
7. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. Science 2004; 305:1622-1625
8. Medina E, North RJ. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 1998;93:270-274
9. Chapuis L, Ji B, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Grosset JH. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med 1994;150:1355-1362
10. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 2003;47:783-785
11. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004;170:1131-1134
12. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003;47:3117-3122
13. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004;23:243-255
14. Dickinson J, Guy A, Mitchison DA. Bioavailability of rifampin in experimental murine tuberculosis. Antimicrob Agents Chemother 1992;36:2066-2067
15. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992;36:548-551
16. Orme I. Search for new drugs for treatment of tuberculosis. Antimicrob Agents Chemother 2001;45:1943-1946
17. Byrne ST, Denkin SM, Gu P, Nuermberger E, Zhang Y. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model. J Med Microbiol 2007;56:1047-1051
18. Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005;49:2289-2293
19. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokineticspharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-2124
20. Jayaram R, Shandil RK, Gaonkar S, et al. Isoniazid pharmacokinetics- pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48:2951-2957
21. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-534
22. Tarn CM, Chan SL, Kam KM, Goodall RL, Mitchison DA. Rifapentine and isoniazid in the continuation phase of a 6-month regimen: final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis 2002;6:3-10
23. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999;353:1843-1847
24. Rosenthal IM, Williams K, Tyagi S, et al. Potent twiceweekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 2006;174:94-101
25. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344
26. Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1980;1:231-241
27. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000;4:796-806
28. Burman WJ. The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Am J Med Sci 1997; 313:355-363
29. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-227
30. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466
31. Nuermberger E, Rosenthal I, Tyagi S, et al. Combination chemotherapy with the nitroimidazopyran PA-824 and firstline drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2006;50:2621-2625
32. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-426
33. Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2809-2812
34. Canetti G. The Tubercle Bacillus in the Pulmonary Lesions of Man. New York: Springer; 1955
35. Opie EJ, Aronson JD. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch Pathol Lab Med 1927;4:1-21
36. McCune RM, Tompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. J Exp Med 1956;104:737-802
37. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-1193
38. Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun 2004;72:1065-1071
39. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001;15:215-222
40. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-2457
41. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351:786-792
42. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000;283:1445-1450
43. Ji B, Truffot-Pernot C, Lacroix C, et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993;148:1541-1546
44. Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 2005; 172:1452-1456
45. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006;173:922-926
46. Dhillon J, Dickinson JM, Sole K, Mitchison DA. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996;40:552-555
47. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosser J, Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993;37:407-413
48. Karlson AG. Therapeutic effect of ethambutol on experimental tuberculosis of guinea pigs. Am Rev Respir Dis 1961; 84:902-904
49. Karlson AG, Feldman WH. Isoniazid in experimental tuberculosis of guinea pigs infected with tubercle bacilli resistant to streptomycin and to para-aminosalicylic acid. Am Rev Tuberc 1952;66:477-485
50. Bjerkedal T, Palmer CE. Effect of isoniazid prophylaxis in experimental tuberculosis in guinea pigs: action of isoniazid in vivo. Am J Hyg 1962;76:89-123
51. Dickinson JM, Mitchison DA. Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol. Tubercle 1976;57:251-258
52. Helke KL, Mankowski JL, Manabe YC. Animal models of cavitation in pulmonary tuberculosis. Tuberculosis (Edinb) 2006;86:337-348
53. Elwood RL, Wilson S, Blanco JC, et al. The American cotton rat: a novel model for pulmonary tuberculosis. Tuberculosis (Edinb) 2007;87:145-154
54. Karakousis PC, Yoshimatsu T, Lamichhane G, et al. Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 2004;200:647-657